HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Dr. Tolaney on Sequencing Strategies in Metastatic HER2+ Breast Cancer

May 6th 2020

Sara M. Tolaney, MD, MPH, discusses sequencing strategies in metastatic HER2-positive breast cancer.

Dr. Favret on the Evolution of Treatment in HER2+ Breast Cancer

May 4th 2020

Anne Favret, MD, discusses the evolution of treatment in HER2-positive breast cancer.

Neratinib Global Access Expands for HER2+ Breast Cancer

April 23rd 2020

Global access to neratinib has increased with the drug now being made commercially available in Singapore.

Closing Thoughts on Metastatic Breast Cancers

April 22nd 2020

Assessing the Value of Personalized Treatment in mBC

April 22nd 2020

Considerations for NGS Testing in mTNBC

April 22nd 2020

Treatment Options in Metastatic TNBC

April 22nd 2020

Role of PARP Inhibition and I/O Therapy in TNBC

April 22nd 2020

IMpassion130 Trial Data on PD-L1+ Tumors in TNBC

April 22nd 2020

Sequencing of Therapy in R/R HER2+ mBC

April 22nd 2020

SOPHIA Trial in R/R HER2+ mBC

April 22nd 2020

HER2CLIMB and NALA Trials: R/R HER2+ mBC

April 22nd 2020

Evolving Treatment Landscape of R/R HER2+ mBC

April 22nd 2020

Payer Coverage of IV Versus Oral Therapy in mBC

April 22nd 2020

Compliance and Adherence to Therapy in mBC

April 22nd 2020

Advantages of Oral Taxanes in mBC

April 22nd 2020

Payer Coverage on Repeat Biopsy in mBC

April 22nd 2020

Payer Perspective of Coverage on Cancer Therapies

April 22nd 2020

SOLAR-1 Trial in Metastatic Breast Cancer

April 22nd 2020

Treatment After Progression on CDK 4/6i in mBC

April 22nd 2020